Cangrelor (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Cangrelor" in English language version.

refsWebsite

Global rank English rank

10doi.org

2^nd place

10nih.gov

4^th place

3semanticscholar.org

11^th place

8^th place

2hpfb-dgpsa.ca

low place

1canada.ca

1,712^th place

1,063^rd place

1medscape.com

719^th place

636^th place

1seekingalpha.com

5,344^th place

3,420^th place

1web.archive.org

1^st place

1fda.gov

447^th place

338^th place

1patents.google.com

1,182^nd place

725^th place

1sciencedirect.com

149^th place

178^th place

1worldcat.org

5^th place

canada.ca

"Notice: Multiple Additions to the Prescription Drug List (PDL) [2023-03-08]". Health Canada. 8 March 2023. Retrieved 21 March 2023.

doi.org

Norgard NB, Hann CL, Dale GL (2009). "Cangrelor attenuates coated-platelet formation". Clinical and Applied Thrombosis/Hemostasis. 15 (2): 177–182. doi:10.1177/1076029608321437. PMID 18796456. S2CID 23639481.
Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, et al. (April 2013). "Effect of platelet inhibition with cangrelor during PCI on ischemic events". The New England Journal of Medicine. 368 (14): 1303–1313. doi:10.1056/NEJMoa1300815. PMID 23473369.
Lange RA, Hillis LD (April 2013). "The duel between dual antiplatelet therapies". The New England Journal of Medicine. 368 (14): 1356–1357. doi:10.1056/NEJMe1302504. PMID 23473370.
Kubica J, Kozinski M, Navarese EP, Tantry U, Kubica A, Siller-Matula JM, et al. (May 2014). "Cangrelor: an emerging therapeutic option for patients with coronary artery disease". Current Medical Research and Opinion. 30 (5): 813–828. doi:10.1185/03007995.2014.880050. PMID 24393016. S2CID 30451326.
Angiolillo DJ, Capranzano P (August 2008). "Pharmacology of emerging novel platelet inhibitors". American Heart Journal. 156 (2 Suppl): S10 – S15. doi:10.1016/j.ahj.2008.06.004. PMID 18657681.
Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, et al. (April 2013). "Effect of platelet inhibition with cangrelor during PCI on ischemic events". The New England Journal of Medicine. 368 (14): 1303–1313. doi:10.1056/nejmoa1300815. PMID 23473369.
Serebruany VL, Sibbing D, DiNicolantonio JJ (2014). "Dyspnea and reversibility of antiplatelet agents: ticagrelor, elinogrel, cangrelor, and beyond". Cardiology. 127 (1): 20–24. doi:10.1159/000354876. PMID 24192670. S2CID 207707382.
Flick AC, Ding HX, Leverett CA, Kyne RE, Liu KK, Fink SJ, O'Donnell CJ (August 2017). "Synthetic Approaches to the New Drugs Approved During 2015". Journal of Medicinal Chemistry. 60 (15): 6480–6515. doi:10.1021/acs.jmedchem.7b00010. PMID 28421763.
Almond MR, Collins JL, Reitter BE, Rideout JL, Freeman GA, St Clair MH (7 October 1991). "Synthesis of 2-amino-9-(3′-azido-2′,3′-dideoxy-beta-D-erythro-pentofuranosyl)-6-methoxy-9H-purine (AzddMAP) and AzddGuo". Tetrahedron Letters. 32 (41): 5745–5748. doi:10.1016/S0040-4039(00)93545-7. ISSN 0040-4039.
Yoshikawa M, Kato T, Takenishi T (December 1967). "A novel method for phosphorylation of nucleosides to 5'-nucleotides". Tetrahedron Letters. 8 (50): 5065–5068. doi:10.1016/S0040-4039(01)89915-9. PMID 6081184.

fda.gov

"FDA approves new antiplatelet drug used during heart procedure" (Press release). U.S. Food and Drug Administration. 22 June 2015. Archived from the original on 23 June 2015.

hpfb-dgpsa.ca

dhpp.hpfb-dgpsa.ca

"Details for: Kengrexal". Health Canada. 30 November 2023. Retrieved 3 March 2024.
"Summary Basis of Decision for Kengrexal". Health Canada. 23 May 2023. Retrieved 5 June 2023.

medscape.com

CHAMPION Trials With Cangrelor Stopped for Lack of Efficacy

nih.gov

pubmed.ncbi.nlm.nih.gov

Norgard NB, Hann CL, Dale GL (2009). "Cangrelor attenuates coated-platelet formation". Clinical and Applied Thrombosis/Hemostasis. 15 (2): 177–182. doi:10.1177/1076029608321437. PMID 18796456. S2CID 23639481.
Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, et al. (April 2013). "Effect of platelet inhibition with cangrelor during PCI on ischemic events". The New England Journal of Medicine. 368 (14): 1303–1313. doi:10.1056/NEJMoa1300815. PMID 23473369.
Lange RA, Hillis LD (April 2013). "The duel between dual antiplatelet therapies". The New England Journal of Medicine. 368 (14): 1356–1357. doi:10.1056/NEJMe1302504. PMID 23473370.
Kubica J, Kozinski M, Navarese EP, Tantry U, Kubica A, Siller-Matula JM, et al. (May 2014). "Cangrelor: an emerging therapeutic option for patients with coronary artery disease". Current Medical Research and Opinion. 30 (5): 813–828. doi:10.1185/03007995.2014.880050. PMID 24393016. S2CID 30451326.
Angiolillo DJ, Capranzano P (August 2008). "Pharmacology of emerging novel platelet inhibitors". American Heart Journal. 156 (2 Suppl): S10 – S15. doi:10.1016/j.ahj.2008.06.004. PMID 18657681.
Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, et al. (April 2013). "Effect of platelet inhibition with cangrelor during PCI on ischemic events". The New England Journal of Medicine. 368 (14): 1303–1313. doi:10.1056/nejmoa1300815. PMID 23473369.
Serebruany VL, Sibbing D, DiNicolantonio JJ (2014). "Dyspnea and reversibility of antiplatelet agents: ticagrelor, elinogrel, cangrelor, and beyond". Cardiology. 127 (1): 20–24. doi:10.1159/000354876. PMID 24192670. S2CID 207707382.
Flick AC, Ding HX, Leverett CA, Kyne RE, Liu KK, Fink SJ, O'Donnell CJ (August 2017). "Synthetic Approaches to the New Drugs Approved During 2015". Journal of Medicinal Chemistry. 60 (15): 6480–6515. doi:10.1021/acs.jmedchem.7b00010. PMID 28421763.
Yoshikawa M, Kato T, Takenishi T (December 1967). "A novel method for phosphorylation of nucleosides to 5'-nucleotides". Tetrahedron Letters. 8 (50): 5065–5068. doi:10.1016/S0040-4039(01)89915-9. PMID 6081184.

dailymed.nlm.nih.gov

"Kengreal- cangrelor injection, powder, lyophilized, for solution". DailyMed. 6 September 2022. Retrieved 3 March 2024.

patents.google.com

CN105481922A, 周峰; 金华 & 郑永勇 et al., "一种坎格雷洛中间体的制备方法", issued 13 April 2016

sciencedirect.com

Almond MR, Collins JL, Reitter BE, Rideout JL, Freeman GA, St Clair MH (7 October 1991). "Synthesis of 2-amino-9-(3′-azido-2′,3′-dideoxy-beta-D-erythro-pentofuranosyl)-6-methoxy-9H-purine (AzddMAP) and AzddGuo". Tetrahedron Letters. 32 (41): 5745–5748. doi:10.1016/S0040-4039(00)93545-7. ISSN 0040-4039.

seekingalpha.com

Napodano J (13 May 2009). "What Cangrelor Failure Means to Medicines". Seeking Alpha.

semanticscholar.org

api.semanticscholar.org

Norgard NB, Hann CL, Dale GL (2009). "Cangrelor attenuates coated-platelet formation". Clinical and Applied Thrombosis/Hemostasis. 15 (2): 177–182. doi:10.1177/1076029608321437. PMID 18796456. S2CID 23639481.
Kubica J, Kozinski M, Navarese EP, Tantry U, Kubica A, Siller-Matula JM, et al. (May 2014). "Cangrelor: an emerging therapeutic option for patients with coronary artery disease". Current Medical Research and Opinion. 30 (5): 813–828. doi:10.1185/03007995.2014.880050. PMID 24393016. S2CID 30451326.
Serebruany VL, Sibbing D, DiNicolantonio JJ (2014). "Dyspnea and reversibility of antiplatelet agents: ticagrelor, elinogrel, cangrelor, and beyond". Cardiology. 127 (1): 20–24. doi:10.1159/000354876. PMID 24192670. S2CID 207707382.

web.archive.org

"FDA approves new antiplatelet drug used during heart procedure" (Press release). U.S. Food and Drug Administration. 22 June 2015. Archived from the original on 23 June 2015.

worldcat.org

search.worldcat.org

Almond MR, Collins JL, Reitter BE, Rideout JL, Freeman GA, St Clair MH (7 October 1991). "Synthesis of 2-amino-9-(3′-azido-2′,3′-dideoxy-beta-D-erythro-pentofuranosyl)-6-methoxy-9H-purine (AzddMAP) and AzddGuo". Tetrahedron Letters. 32 (41): 5745–5748. doi:10.1016/S0040-4039(00)93545-7. ISSN 0040-4039.